Takeda Settles Tax Dispute with Irish Revenue over Break Fee Received by Shire Takeda (TSE:4502/NYSE:TAK) today announced that it agreed with the Irish Revenue Commissioners (“Irish Revenue”) to settle a…
Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas Takeda (TSE:4502/NYSE: TAK) today announced that the Phase 3 ADMIRE-CD II study,…
Dating a overseas woman see page is a fascinating and rewarding experience. Nevertheless, it is important to be aware of cultural variations. For case, views toward marriage and home, identity…
DePuy Synthes Receives FDA Clearance for TriLEAP™ Lower Extremity Anatomic Plating System Today, Johnson & Johnson MedTech* announced that DePuy Synthes, The Orthopaedics Company of Johnson & Johnson**, has received…
R&D Postdoctoral Challenge is a ground-breaking initiative fostering collaboration, innovation and global diversity AstraZeneca announced today eight winners of the 2023 R&D Postdoctoral Challenge and agreed to fund their postdoctoral positions at…
.S. FDA Approves Pfizer’s VELSIPITY™ for Adults with Moderately to Severely Active Ulcerative Colitis (UC) Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has…
U.S. FDA Approves Pfizer’s BRAFTOVI® + MEKTOVI® for BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has…
Bayer invests 250 million USD in new cell therapy manufacturing facility in the U.S. Bayer AG has opened a new cell therapy production plant in Berkeley, California, USA, to bring…
Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease Merck (NYSE: MRK), known…
Merck Announces Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of Overall Survival (OS) in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC) Merck (NYSE: MRK), known as…
Roche’s Vabysmo maintained vision improvements with extended treatment intervals up to four months for people with retinal vein occlusion (RVO) in phase III studies Roche (SIX: RO, ROG; OTCQX: RHHBY)…
Janssen Highlights Latest Research for TREMFYA® (guselkumab) and Investigational Targeted Oral Peptide JNJ-2113 in Moderate to Severe Plaque Psoriasis at the European Academy of Dermatology and Venereology (EADV) Congress Janssen Pharmaceuticals,…